Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Assenagon Asset Management S.A. raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 79.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 684,889 shares of the biotechnology company’s stock after acquiring an additional 304,264 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.50% of Arrowhead Pharmaceuticals worth $45,470,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. Salomon & Ludwin LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth approximately $34,000. Federated Hermes Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth approximately $52,000. Smartleaf Asset Management LLC grew its position in Arrowhead Pharmaceuticals by 2,186.5% during the third quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,618 shares during the period. Finally, Virtus Advisers LLC purchased a new stake in Arrowhead Pharmaceuticals during the second quarter valued at approximately $34,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the transaction, the chief operating officer directly owned 474,908 shares in the company, valued at $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Richard Anzalone sold 13,187 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $66.10, for a total value of $871,660.70. Following the completion of the transaction, the chief executive officer directly owned 3,792,739 shares of the company’s stock, valued at approximately $250,700,047.90. This trade represents a 0.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 172,100 shares of company stock valued at $11,274,732 in the last ninety days. Insiders own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of several analyst reports. Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 10th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. Royal Bank Of Canada lifted their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Finally, B. Riley Financial boosted their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $56.27 on Wednesday. The firm has a market cap of $7.88 billion, a P/E ratio of 36.78 and a beta of 1.23. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $76.76. The company has a 50 day simple moving average of $63.20 and a two-hundred day simple moving average of $53.12. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.39) earnings per share. Equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.